Shiliang Li

 
QQ:      798361065
 
Education & Work Experience                                                                     
2007.09 ~ 2011.06   B.E.,  School of Pharmacy, major in Pharmaceutical engineering and
                                 minor in English, East China University of Science and Technology; 
2011.09 ~ 2016.06   Ph.D., School of Pharmacy, East China University of Science and
                                 Technology. 
2016.06 ~ present   Post Doctor, School of Pharmacy, East China University of Science
                                 and Technology.
 
Research Interests                                                                                        
1. Homology modeling, virtual screening, lead discoverying and target prediction; 
2. Network pharmacology research and application;
3. Free energy landscape of ligand-receptor interaction construction;
4. Binding kinetics prediction and it's application in drug discovery;
5. Study of polypharmacology based on 3D Drug binding site similarity.
 
Publications                                                                                                    
  1.  Shiliang li, Yi Zhou, Weiqiang Lu, Ye Zhong, Jin Huang*, zhenjiang zhao, Xiaofeng Liu*, Yufang Xu, Honglin Li. Identification of Inhibitors against p90 Ribosomal S6 Kinase 2 (RSK2) through Structure-based Virtual Screening with the Inhibitor-constrained Refined Homology Model. J. Chem. Inf. Model., 2011, 51(11), 2939–2947.
  2.  Shiliang Li*, Guoqin Luan*, Xiaoli Ren*, Wenlin Song, Liuxin Xu, Minghao Xu, Junsheng Zhu, Dong Dong, Yanyan Diao, Xiaofeng Liu, Lili Zhu, Rui Wang, Zhenjiang Zhao, Yufang Xu, Honglin Li. Rational Design of Benzylidenehydrazinyl-Substituted Thiazole Derivatives as Potent Inhibitors of Human Dihydroorotate Dehydrogenase with in Vivo Anti-arthritic Activity. Sci. Rep., 2015. 5 : 14836.
  3.   Shiliang Li, Xiaojuan Yu, Chuanxin Zou, Jiayu Gong, Xiaofeng Liu, Honglin Li. Are Topological Properties of Drug Targets Based on Protein-Protein Interaction Network Ready to Predict Potential Drug Targets?. Comb. Chem. High Throughput Screen., 2016. 2 : 109-120.
  4.  Shiliang Li, Yuwei Song, Xiaofeng Liu, Honglin Li. A Rapid Python-Based Methodology for Target-Focused Combinatorial Library Design. Comb. Chem. High Throughput Screen., 2016. 1 : 25-35.
  5.  Wei Zhou*, Shiliang Li*, Weiqiang Lu*, Jun Yuan, Yufang Xu, Honglin Li, Jin Huang, Zhenjiang Zhao. Isoindole-1,3-dione Derivatives as RSK2 Inhibitors: Synthesis, Molecular Docking Simulation and SAR Analysis. Med. Chem. Commun., 2016. 7 : 292-296.
  6.  Wenlin Song*, Shiliang Li*, Yi Tong*, Jiawei Wang, Lina Quan, Zhuo Chen, Zhenjiang Zhao, Yufang Xu, Lili Zhu, Xuhong Qian, Honglin Li. Structure-based Design of Potent Human Dihydroorotate Dehydrogenase Inhibitors as Anticancer Agents. Med. Chem. Commun.. DOI: 10.1039/C6MD00179C.
  7. Jun Yuan*, Ye Zhong*, Shiliang Li, Xue Zhao, Guoqin Luan, Zhenjiang Zhao, Jin Huang, Honglin Li, Yufang Xu. Triazole and Benzotrizaole Derivatives as Novel Inhibitors for p90 Ribosomal S6 Protein Kinase 2: Synthesis, Molecular Docking and SAR Analysis. Chin. J. Chem., 2013. 31(9) : 1192-1198.
  8.  Jiawei Wang, Yanyan Diao, Junsheng Zhu, Shiliang Li, Zhenjiang Zhao, Honglin Li, Lili Zhu. Biological Evaluation of Quinoline Derivatives as Inhibitors of Human Dihydroorotate Dehydrogenase. Med. Chem. Commun., 2016, DOI: 10.1039/C6MD00024J.
  9.  Junsheng Zhu*, Le Han*, Yanyan Diao*, Xiaoli Ren, Minghao Xu, Liuxin Xu, Shiliang Li, Qiang Li, Dong Dong, Jin Huang, Xiaofeng Liu, Zhenjiang zhao, Rui Wang, Lili Zhu,* Yufang Xu, Xuhong Qian, Honglin Li. Design, Synthesis, X-ray Crystallographic Analysis, and Biological Evaluation of Thiazole-Derivatives as Potent and Selective Inhibitors of Human Dihydroorotate Dehydrogenase. J. Med. Chem., 2015. 58 : 1123-1139.
  10. Tianfeng Xu, Lianwen Zhang, Shilin Xu, Chaoyie Yang, Jinfeng Luo, Fang Ding, Xiaoyun Lu, Yinxue Liu, Zhengchao Tu, Shiliang Li, Duanqing Pei, Qian Cai, Honglin Li, Xiaomei Ren, Shaomeng Wang, Ke Ding. Pyrimido[4,5-d]pyrimidin-4(1H)-one Derivatives as Selective Inhibitors of EGFR Threonine790 to Methionine790 (T790M) Mutants. Angew. Chem. Int. Ed. Engl., 2013. 125 (32) : 8545-8548.
  11.  Xia Wang, Haipeng Chen, Feng Yang, Jiayu Gong, Shiliang Li, Jianfeng Pei, Xiaofeng Liu, Hualiang Jiang, Luhua Lai, Honglin Li. iDrug: a Web-accessible and Interactive Drug Discovery and Design Platform. J. Cheminform., 2014. 6: 28.
  12.  Shoude Zhang, Lei Shan, Qiao Li, Xia Wang, Shiliang Li, Yuan Zhang, Jianjun Fu, Xiaofeng Liu, Honglin Li, Weidong Zhang. Systematic Analysis of the Multiple Bioactivities of Green Tea through a Network Pharmacology Approach. Evid. Based Complement. Alternat. Med., 2014. 2014 : 512081.

User Login


Contact us


Honglin Li's Lab
Shanghai Key Laboratory of New Drug Design
School of Pharmacy
East China University of Sci. & Tech.
Room 527, Building 18, 130 Meilong Road,
Shanghai, 200237, P. R. China
Tel: (86) 21 6425 0213
Prof. Honglin Li
hlli@ecust.edu.cn

Copyright © 2019 Prof. HongLin Li's Group, School of Pharmacy, East China University of Science & Technology · All Right Reserved.
沪ICP备19004698号-1 |  沪公网安备31011302004713号